Accueil Ernstrade Bourse
plus500

 
Canada

Welichem Biotech Inc. is a clinical stage biotech company engaging in the discovery and development of novel small molecule therapeutics for unmet medical needs. Before 2012, the Company was dedicated to research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives. WBI-1001 was a novel anti-inflammatory agent developed by the Company as a topical treatment for inflammatory skin diseases such as psoriasis and atopic dermatitis. Four clinical studies were completed by the Company using WBI-1001 creams for the treatment of atopic dermatitis and psoriasis. In July 2012, the WBI- 1001 technology was acquired by Stiefel, A Glaxo Group Limited (GSK) company, for further development, regulatory approval, and commercialization.



 

http://www.welichem.com/

Copyright  2017 Ernstrade